Tuspetinib

Aptose Biosciences initiated the TUSCANY Phase 1/2 study, dosing patients with the TUS+VEN+AZA triplet therapy for newly diagnosed AML. This combination aims to offer a durable, well-tolerated treatment across diverse AML populations, showing promise for high response rates and longer survival without the toxicities of other agents.

Aptose Biosciences Inc. is advancing TUS+VEN+AZA triplet therapy for newly diagnosed AML patients, showing broad efficacy and safety across AML populations, including FLT3 wildtype and prior-VEN failure cases. TUS targets VEN resistance, potentially establishing a new standard of care for chemotherapy-ineligible AML patients.

Aptose Biosciences Inc. and the National Cancer Institute (NCI) have entered a Cooperative Research and Development Agreement (CRADA) to collaborate on the clinical development of Aptose’s lead compound tuspetinib (TUS) in NCI’s myeloMATCH trials for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Tuspetinib, an inhibitor of key signaling kinases, will be part of precision medicine trials aiming to develop tailored drug combinations. Aptose is also developing tuspetinib in a triple drug combination (TUS+VEN+AZA) for newly diagnosed AML patients unfit for chemotherapy.

Aptose Biosciences partners with National Cancer Institute to develop tuspetinib for acute myeloid leukemia and myelodysplastic syndromes in myeloMATCH trials, aiming to enhance treatment options through targeted drug combinations.

Aptose Biosciences signs CRADA with NCI to develop tuspetinib for AML and MDS in myeloMATCH trials, aiming for tailored drug combinations. Separately, Aptose plans Phase 1/2 TUSCANY study for triple drug combo (tuspetinib, venetoclax, azacitidine) in AML patients unfit for chemotherapy, set to begin Q4.

Aptose Biosciences announced financial results for Q3 2024, highlighting a net loss decrease to $7.0 million. The company secured a $10 million loan from Hanmi to support tuspetinib development, showcasing its potential in AML triplet therapies. Aptose faces challenges with Nasdaq compliance, aiming to address stockholders' equity and minimum bid price requirements. Key milestones include initiating TUS+VEN+AZA triplet dosing in newly diagnosed AML patients and reporting data from ongoing studies.